We recently compiled a list of the 10 Best Gene Therapy Stocks to Buy Right Now. In this article, we are going to take a look ...

根据最近的SEC文件显示，bluebird bio, Inc.（纳斯达克股票代码：BLUE）的首席医疗官Richard A.

根据提交给美国证券交易委员会的文件显示，bluebird bio, Inc.（纳斯达克股票代码：BLUE）总裁兼首席执行官Andrew Obenshain最近出售了部分公司持股。Obenshain以每股9.24美元的价格出售了140股普通股，总计约1,293美元。根据 InvestingPro 的数据，该公司股票目前交易价格为8.46美元，过去一年下跌近70%，显示出显著的波动性。

In this article, we are going to take a look at where bluebird bio, Inc. (NASDAQ:BLUE) stands against the other gene therapy stocks. Gene therapy is referred to as a medical technique that ...

bluebird bio, Inc. is a clinical-stage biotechnology company, which engages in researching, developing and commercializing potentially transformative gene therapies for severe genetic diseases.

Short interest is currently not available. Nasdaq provides information of company’s short interest and the average days it takes to cover them. Short interest and days to cover can be used to ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Barclays analyst Gena Wang maintained a Buy rating on Bluebird Bio (BLUE – Research Report) yesterday and set a price target of $40.00. Discover the latest stocks recommended by top Wall Street ...

Bluebird Bio is listed on the CBOE trading with ticker code BLUE.US. It has a market capitalisation of $73.89m, with approximately 194.44m shares in issue. Over the last year, Bluebird Bio share ...

FDA-Approved Sickle Cell Therapies From Bluebird Bio And Vertex Join Medicaid Innovation Program CMS launches an outcomes-based model to expand access to FDA-approved gene therapies for sickle ...